Monoamine Contributions to Neurocircuitry in Eating Disorders
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02020408|
Recruitment Status : Completed
First Posted : December 24, 2013
Last Update Posted : May 18, 2016
|Condition or disease||Intervention/treatment||Phase|
|Eating Disorder||Drug: [11C]raclopride Drug: [11C]DASB Drug: amphetamine||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||88 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Basic Science|
|Official Title:||Monoamine Contributions to Neurocircuitry in Eating Disorders|
|Study Start Date :||May 2011|
|Actual Primary Completion Date :||April 2016|
|Actual Study Completion Date :||April 2016|
Experimental: [11C]raclopride, [11C]DASB, amphetamine
One time administration of oral amphetamine based on subject's weight (0.5 mg/kg). One PET scan using [11C]DASB. Two PET scans using [11C]raclopride.
1.[11C]raclopride -The change (Δ) in BPND (the difference between the [11C]raclopride BPND at baseline and post-AMPH treatment normalized to the baseline BPND
Other Name: Raclopride, serial number 009
BPND of [11C]DASB.
Other Name: DASB, serial number 0011
The change (Δ) in BPND (the difference between the [11C]raclopride BPND at baseline and post-AMPH treatment normalized to the baseline BPND.
Other Name: dextroamphetamine
- 1. 5-HT transporter binding and Dopamine (DA) D2/D3 binding as measured during the PET scan [ Time Frame: 90 minute PET scan ]Use PET and [11C]DASB and [11C]raclopride to explore 5-HTT and DA D2/D3 receptor binding potential in cortical, subcortical and striatal ROIs.
- Change in [11C]raclopride binding potential from baseline to post-amphetamine administration as measured during the two 90 min PET scans. [ Time Frame: Two 90 min PET scans ]The change (Δ) in BPND (the difference between the [11C]raclopride BPND at baseline and post-AMPH treatment normalized to the baseline BPND).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02020408
|United States, California|
|University of California San Diego|
|San Diego, California, United States, 92102|
|Principal Investigator:||Walter Kaye, MD||UCSD|